Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs

Bibliography

• GREEN GA: Understanding NSAIDs: from aspirin to COX-2. Clin. Cornerstone (2001) 3:50-60.
   PubMedGoogle Scholar
• AMERICAN COLLEGE OF RHEUMATOLOGY: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. (2000) 43:1905-1915.
   PubMed Web of Science ®Google Scholar
• FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. (2001) 345:433-442.
   PubMed Web of Science ®Google Scholar
• RUBIN BR, BURTON R, NAVARRA S et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. (2004) 50:598-606.
   PubMed Web of Science ®Google Scholar
• GOSSEC L, VAN DER HEIJDE D, MELIAN A et al.: The Efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann. Rheum. Dis. (2005) In press.
   Google Scholar
• STEINBACH G, LYNCH PM, PHILLIPS RK et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. (2000) 342:1946-1952.
   PubMed Web of Science ®Google Scholar
• ASANO TK, MCLEOD RS: Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst. Rev. (2004):CD004079.
   PubMedGoogle Scholar
• PATRONO C, COLLER B, DALEN JE et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest (2001) 119:39S-63S.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71-86.
   PubMed Web of Science ®Google Scholar
• SANMUGANATHAN PS, GHAHRAMANI P, JACKSON PR, WALLIS EJ, RAMSAY LE: Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart (2001) 85:265-271.
   PubMed Web of Science ®Google Scholar
• HAYDEN M, PIGNONE M, PHILLIPS C, MULROW C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. (2002) 136:161-172.
   PubMed Web of Science ®Google Scholar
• MILLER MG, LUCAS BD, PAPADEMETRIOU V, ELHABYAN AK: Aspirin under fire: aspirin use in the primary prevention of coronary heart disease. Pharmacotherapy (2005) 25:847-861.
   PubMed Web of Science ®Google Scholar
• CHIOLÉRO A, MAILLARD M, BURNIER M: Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert Opin. Drug Saf. (2002) 1:45-52.
   PubMedGoogle Scholar
• FINCKH A, ARONSON MD: Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann. Intern. Med. (2005) 142:212-214.
   PubMed Web of Science ®Google Scholar
• BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343:1520-1528.
   PubMed Web of Science ®Google Scholar
• BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. (2005) 352:1092-1102.
   PubMed Web of Science ®Google Scholar
• SOLOMON SD, MCMURRAY JJ, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. (2005) 352:1071-1080.
   PubMed Web of Science ®Google Scholar
• NUSSMEIER NA, WHELTON AA, BROWN MT et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. (2005) 352:1081-1091.
   PubMed Web of Science ®Google Scholar
• GARCIA RODRIGUEZ LA, VARAS-LORENZO C, MAGUIRE A, GONZALEZ-PEREZ A: Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation (2004) 109:3000-3006.
   PubMed Web of Science ®Google Scholar
• HIPPISLEY-COX J, COUPLAND C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or traditional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br. Med. J. (2005) 330:1366-1372.
   PubMed Web of Science ®Google Scholar
• JOHNSEN SP, LARSSON H, TARONE RE et al.: Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch. Intern. Med. (2005) 165:978-984.
   PubMed Web of Science ®Google Scholar
• KIMMEL SE, BERLIN JA, REILLY M et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med. (2005) 142:157-164.
   PubMed Web of Science ®Google Scholar
• JUNI P, NARTEY L, REICHENBACH S et al.: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 364:2021-2029.
   PubMed Web of Science ®Google Scholar
• BURNIER M: The safety of rofecoxib. Expert. Opin. Drug Saf. (2005) 4:491-499.
   PubMedGoogle Scholar
• WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1999) 340:1888-1899.
   PubMed Web of Science ®Google Scholar
• KONSTAM MA, WEIR MR, REICIN A et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 104:2280-2288.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286:954-959.
   PubMed Web of Science ®Google Scholar
• KURUMBAIL RG, STEVENS AM, GIERSE JK et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384:644-648.
   PubMed Web of Science ®Google Scholar
• FELDMAN M, MCMAHON AT: Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med. (2000) 132:134-143.
   PubMed Web of Science ®Google Scholar
• FITZGERALD GA: The choreography of cyclooxygenases in the kidney. J. Clin. Invest. (2002) 110:33-34.
   PubMed Web of Science ®Google Scholar
• FEENSTRA J, HEERDINK ER, GROBBEE DE, STRIKER BH. Association of non-steroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch. Int. Med. (2002) 162:265-270
   PubMed Web of Science ®Google Scholar
• KANNEL WB: Hypertension and the risk of cardiovascular disease. In: Hypertension: Pathophysiology, Diagnosis, and Management. Laragh JH, Brenner BM (Eds). Raven Press. New York. (1990):101-117.
   Google Scholar
• BRATER DC, HARRIS RC, REDFERN JS, GERTZ BJ: Renal effects of COX-2 selective inhibitors. Am. J. Nephrol. (2001) 21:1-15.
   PubMed Web of Science ®Google Scholar
• MURATA T, USHIKUBI F, MATSUOKA T et al.: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 388:678-682.
   PubMed Web of Science ®Google Scholar
• KENNEDY CR, ZHANG Y, BRANDON S et al.: Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat. Med. (1999) 5:217-220.
   PubMed Web of Science ®Google Scholar
• CHENG Y, AUSTIN SC, ROCCA B et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 296:539-541.
   PubMed Web of Science ®Google Scholar
• EGAN KM, LAWSON JA, FRIES S et al.: COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 306:1954-1957.
   PubMed Web of Science ®Google Scholar
• VAN HECKEN A, SCHWARTZ JI, DEPRE M et al.: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. (2000) 40:1109-1120.
   PubMed Web of Science ®Google Scholar
• CAPONE ML, TACCONELLI S, SCIULLI MG et al.: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation (2004) 109:1468-1471.
   PubMed Web of Science ®Google Scholar
• CATELLA-LAWSON F, REILLY MP, KAPOOR SC et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. (2001) 345:1809-1817.
   PubMed Web of Science ®Google Scholar
• PATEL TN, GOLDBERG KC: Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch. Intern. Med. (2004) 164:852-856.
   PubMed Web of Science ®Google Scholar
• KONSTANTINOPOULOS PA, LEHMANN DF: The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J. Clin. Pharmacol. (2005) 45:742-750.
   PubMed Web of Science ®Google Scholar
• BOLTEN WW: The problem of the atherothrombotic potential of nonsteroidal anti-inflammatory drugs. Ann. Rheum. Dis. (2005) In press.
   PubMedGoogle Scholar
• LEHMANN DF: Arthritis medications and cardiovascular events. JAMA (2005) 293:1976-1977.
   PubMedGoogle Scholar
• HARRIS RC: Cyclooxygenase-2 inhibition and renal physiology. Am. J. Cardiol. (2002) 89:10D-17D.
   PubMed Web of Science ®Google Scholar
• HARRIS RC, BREYER MD: Physiological regulation of cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal Physiol. (2001) 281:F1-F11.
   PubMed Web of Science ®Google Scholar
• KOMERS R, ANDERSON S, EPSTEIN M: Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am. J. Kidney. Dis. (2001) 38:1145-1157.
   PubMed Web of Science ®Google Scholar
• STICHTENOTH DO, FROLICH JC: COX-2 and the kidneys. Curr. Pharm. Design (2000) 6:1737-1753.
   PubMed Web of Science ®Google Scholar
• FRISHMAN WH: Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am. J. Cardiol. (2002) 89:18D-25D.
   PubMedGoogle Scholar
• SCHOOLEY RT, WAGLEY PF, LIETMAN PS: Edema associated with ibuprofen therapy. JAMA (1977) 237:1716-1717.
   PubMed Web of Science ®Google Scholar
• HEERDINK ER, LEUFKENS HG, HERINGS RM et al.: NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch. Intern. Med. (1998) 158:1108-1112.
   PubMed Web of Science ®Google Scholar
• PAGE J, HENRY D: Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch. Intern. Med. (2000) 160:777-784.
   PubMed Web of Science ®Google Scholar
• POPE JE, ANDERSON JJ, FELSON DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch. Intern. Med. (1993) 153:477-484.
   PubMed Web of Science ®Google Scholar
• FIERRO-CARRION GA, RAM CV: Nonsteroidal anti-inflammatory drugs (NSAIDs) and blood pressure. Am. J. Cardiol. (1997) 80:775-776.
   PubMed Web of Science ®Google Scholar
• JOHNSON AG, NGUYEN TV, DAY RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann. Intern. Med. (1994) 121:289-300.
   PubMed Web of Science ®Google Scholar
• SOWERS JR, WHITE WB, PITT B et al.: The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and Type 2 diabetes mellitus. Arch. Intern. Med. (2005) 165:161-168.
   PubMed Web of Science ®Google Scholar
• BARON JA, COLE BF, SANDLERS RS et al.: A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. (2003) 348:891-899
   PubMed Web of Science ®Google Scholar
• RIDKER PM, COOK NR, LEE IM et al.: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. (2005) 352:1293-1304.
   PubMed Web of Science ®Google Scholar
• RAY WA, STEIN CM, HALL K, DAUGHERTY JR, GRIFFIN MR: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet (2002) 359:118-123.
   PubMed Web of Science ®Google Scholar
• SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284:1247-1255.
   PubMed Web of Science ®Google Scholar
• SOLOMON DH, GLYNN RJ, LEVIN R, AVORN J: Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med. (2002) 162:1099-1104.
   PubMed Web of Science ®Google Scholar
• WATSON DJ, RHODES T, CAI B, GUESS HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. (2002) 162:1105-1110.
   PubMed Web of Science ®Google Scholar
• RAHME E, PILOTE L, LELORIER J: Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med. (2002) 162:1111-1115.
   PubMed Web of Science ®Google Scholar
• KIMMEL SE, BERLIN JA, REILLY M et al.: The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Am. Coll. Cardiol. (2004) 43:985-990.
   PubMed Web of Science ®Google Scholar
• MAMDANI M, ROCHON P, JUURLINK DN et al.: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch. Intern. Med. (2003) 163:481-486.
   PubMed Web of Science ®Google Scholar
• GRAHAM DJ, CAMPEN D, HUI R et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet (2005) 365:475-481.
   PubMed Web of Science ®Google Scholar
• FARKOUH ME, KIRSHNER H, HARRINGTON RA et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet (2004) 364:675-684.
   PubMed Web of Science ®Google Scholar
• ZHAO SZ, BURKE TA, WHELTON A, VON ALLMEN H, HENDERSON SC: Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Am. J. Manag. Care (2002) 8:S392-S400.
   PubMed Web of Science ®Google Scholar
• WONG D, WANG M, CHENG Y, FITZGERALD GA: Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr. Opin. Pharmacol. (2005) 5:204-210.
   PubMed Web of Science ®Google Scholar
• FISCHER LM, SCHLIENGER RG, MATTER CM, JICK H, MEIER CR: Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch. Intern. Med. (2004) 164:2472-2476.
   PubMed Web of Science ®Google Scholar
• FISCHER LM, SCHLIENGER RG, MATTER CM, JICK H, MEIER CR: Current use of nonsteroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy (2005) 25:503-510.
   PubMed Web of Science ®Google Scholar